Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Parkinson Disease 1Neuroendocrine Tumors 1

Interventions

apatinib 25Cisplatin 19Capecitabine 17Irinotecan 16Cyclophosphamide 16fludarabine 14Radiotherapy 12Oxaliplatin 12Drug Therapy 12camrelizumab 11Paclitaxel 11S 1 (combination) 10Docetaxel 10Carboplatin 10Fluorouracil 9Blood Specimen Collection 9Bevacizumab 9Nivolumab 8tislelizumab 7Radiation 7Pemetrexed 7Gemcitabine 7Erlotinib Hydrochloride 7Surgical Procedures, Operative 6Neoadjuvant Therapy 6Albumin-Bound Paclitaxel 6toripalimab 5anlotinib 5XELOX 5Tamoxifen 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × OTHER_GOV × Iodine-123 × Clear all
NCT02418247 2017-01-20

Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer

National Cancer Center, Korea

Phase 2/3 Unknown
556 enrolled
Head & Neck

Thyroid Neoplasms

NCT01931488 2013-08-29

124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.

Tel-Aviv Sourasky Medical Center

Phase 2 Unknown
40 enrolled
EndocrineNET

Parkinson Disease, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡